Skip to Main Content

Paper Details

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.
Clin Cancer Res
22
2021
Author NameAffiliation
Obi L GriffithWashington University School of Medicine
Malachi GriffithWashington University School of Medicine
Todd A FehnigerWashington University School of Medicine
  • 1 - 3

Datasets

Release 1.2